Table 1—

Therapies proven effective in diabetes prevention trials

Study (reference)nPopulationAge (years)Duration (years)Follow upIntervention (daily dose)Control subjects (%/year)Relative risk
Finnish DPS (15)522IGT, BMI ≥25 kg/m2553.292Individual diet/exercise60.42 (0.30–070)
DPP (14)2,161*IGT, BMI ≥24 kg/m2, FPG >5.3 (95)51393Individual diet/exercise100.42 (0.34–0.52)
Pan et al. (22)259*IGT (randomized groups)45692Group diet/ exercise160.62 (0.44–0.86)
Kosaka et al. (23)458IGT (men), BMI = 24 kg/m2∼55492Individual diet/exercise20.33 (0.10–1.0)
Indian DPP (24)269*IGT462.595Individual diet/exercise220.71 (0.63–0.79)
DPP (14)2,155*IGT, BMI >24 kg/m2, FPG >5.3512.893Metformin (1,700 mg)100.69 (0.57–0.83)
Indian DPP (24)269*IGT462.595Metformin (500 mg)220.74 (0.65–0.81)
STOP NIDDM (16)1,419IGT, FPG >5.6543.296Acarbose (300 mg)130.75 (0.63–0.90)
XENDOS (18)3,277BMI >30 kg/m243443Orlistat (360 mg)20.63 (0.46–0.86)
DPP (25)1,067*IGT, BMI >24 kg/m2, FPG >5.3510.993Troglitazone (400 mg)120.25 (0.14–0.43)
TRIPOD (26)266Previous GDM352.567Troglitazone (400 mg)120.45 (0.25–0.83)
DREAM (17)5,269IGT or IFG553.094Rosiglitazone (8 mg)90.40 (0.35–0.46)
  • *

    * Number of participants in the indicated comparisons and not the total randomized;

  • calculated from information in the article. DPP, Diabetes Prevention Program; DPS, Diabetes Prevention Study; GDM, gestational diabetes mellitus; STOP, Study to Prevent Non-Insulin Dependent Diabetes; TRIPOD, Troglitazone in Prevention of Diabetes; XENDOS, Xenical in the prevention of Diabetes in Obese Subjects.